Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Inclusion Criteria: * Be ≥18 years of age (or the higher legal age in the jurisdiction in which the study is taking place) at the time of informed consent * Has documented diagnosis of MM according to the IMWG diagnostic criteria (Rajkumar 2011). * Teclistamab or Talquetamab + Tocilizumab: has received 2 or more prior MM therapies including a PI, IMiD and CD38 antibody. * Teclistamab + Oral Dexamethasone: has received 1 or more prior MM therapies including a PI, IMiD and/or CD38 antibody. * Teclistamab or Talquetamab + Tocilizumab: has an ECOG performance status (Oken 1982) of 0 to 1. Teclistamab + Oral Dexamethasone: has an ECOG performance status (Oken 1982) of 0 to 2. * Measurable disease at screening, as assessed by local laboratory, defined by any of the following: * Serum M-protein level ≥0.5 g/dL; or * Urine M-protein level ≥200 mg/24 hours; or * Light chain MM without measurable M-protein in the serum or the urine: serum free light chain (sFLC) ≥10 mg/dL and abnormal serum immunoglobulin kappa lambda FLC ratio. * For participants without measurable disease in the serum, urine, or involved FLC, presence of plasmacytomas (≥2 cm). * Human immunodeficiency virus-positive participants are eligible if they meet all of the following: * No detectable viral load (i.e., \<50 copies/mL) at screening * CD4+ count \>300 cells/mm3 at screening * No acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within 6 months of screening * Receivin…